Skip to main content

Table 1 Characterization of population according to acute pancreatitis severity

From: Red cell distribution width and red cell distribution width to total serum calcium ratio as major predictors of severity and mortality in acute pancreatitis

Variable

Severe acute pancreatitis (n = 91)

Mild acute pancreatitis (n = 91)

pU/pM

aOR, 95 CI in M

Age (yo), μ ± σ

64.8 ± 16.3

67.9 ± 13.7

0.239/−

Male gender, n(%)

53(58.2%)

47(51.6%)

0.228/−

Alcoholism, n(%)

26(28.6%)

14(15.4%)

0.032/−

Smoking, n(%)

0(0.0%)

5(5.5%)

0.023/−

Hospital stay, median(IQR)

1.3(2–83)

8.0(2–25)

0.001/−

Comorbiditiesa, n(%)

75(82.4%)

83(91.2%)

0.08/−

 Hypothyroidism

2(2.2%)

9(9.9%)

0.029/−

 Cerebral vascular accident

9(9.9%)

0(0.0%)

0.002/−

 Chronic renal disease

10(11.0%)

3(3.3%)

0.004/−

Laboratory and gasometrical parameters

 WBC count (cells/mm3), μ ± σ

15,630.0 ± 9030.0

31,165.0 ± 1631.7

0.001/−

 AST (IU/L), μ ± σ

193.5 ± 164.1

778.9 ± 354.6

0.003/−

 ALT (IU/L), μ ± σ

249.7 ± 180.3

445.5 ± 252.8

0.129/−

 Total bilirubin (mg/dL), μ ± σ

2.7 ± 2.6

2.2 ± 1.9

0.363/−

 Platelet count (cells/mm3), μ ± σ

212.2 ± 87.1

208.8 ± 72.8

0.975/−

 BUN (mg/dL), μ ± σ

26.6 ± 17.1

19.4 ± 8.8

0.009/< 0.001

1.002, [1.001;1.007]

 Creatinine (mg/dL), μ ± σ

1.5 ± 1.3

0.9 ± 0.3

< 0.001/−

 INR, μ ± σ

3.0 ± 1.6

1.4 ± 0.2

< 0.001/−

 Albumin (g/dL), μ ± σ

3.6 ± 0.6

4.0 ± 0.7

< 0.001/−

 LDH (IU/L), μ ± σ

503.0 ± 403.7

406.8 ± 305.4

< 0.001/−

 Serum glucose (mg/dL), μ ± σ

168.0 ± 72.6

130.9 ± 35.5

< 0.001/< 0.001

1.002, [1.001;1.317]

 Hemoglobin (mg/dL), μ ± σ

13.8 ± 2.6

13.5 ± 1.4

0.406/−

 Hematocrit (%), μ ± σ

41.5 ± 7.0

40.2 ± 4.3

0.285/−

 Serum amylase (IU/L), μ ± σ

1315.2 ± 1163.3

2049.2 ± 1715.0

0.398/−

 CRP0h (mg/dL), μ ± σ

10.9 ± 9.2

5.0 ± 3.3

< 0.001/−

 CRP24h (mg/dL), μ ± σ

21.1 ± 11.6

11.3 ± 5.8

< 0.001/−

 Lactate (mg/dL), μ ± σ

2.8 ± 1.7

1.5 ± 1.0

< 0.001/−

 D-dimers (μg/mL), μ ± σ

6.6 ± 6.5

1.5 ± 0.3

0.192/−

 Total serum calcium (mg/dL), μ ± σ

8.2 ± 1.2

9.6 ± 0.4

< 0.001/−

 RDW0h (%), μ ± σ

14.6 ± 1.3

12.7 ± 0.5

< 0.001/< 0.001

1.129, [1.065;1.192]

 RDW24h (%), μ ± σ

14.3 ± 1.9

12.8 ± 0.5

< 0.001/0.005

1.015, [1.003;1.055]

 RDW0h-to-total serum calcium ratio, μ ± σ

1.8 ± 0.4

1.3 ± 0.1

< 0.001/< 0.001

1.556, [1.356;1.756]

 RDW0h-to-platelets ratio, μ ± σ

0.08 ± 0.03

0.07 ± 0.02

0.03/−

Prognostic scores

 Ranson score, μ ± σ

2.6 ± 1.2

1.5 ± 0.9

< 0.001/< 0.001

1.043, [1.001;1.088]

 BISAP score, μ ± σ

1.7 ± 0.9

1.0 ± 0.7

< 0.001/< 0.001

1.028, [1.016;1.092]

 Modified Marshall score, μ ± σ

0.8 ± 0.7

0.0 ± 0.0

< 0.001/< 0.001

1.184, [1.112;1.256]

  1. ALT alanine aminotransferase, AST aspartate aminotransferase, aOR adjusted odds ratio, BUN blood urea nitrogen, CRP0h C-reactive protein at 0 h, CRP24h C-reactive protein at 24 h, CI confidence interval, INR international normalized ratio, IQR interquartile range, LDH lactate dehydrogenase, M multivariate analysis, RDW0h red cell distribution width at 0 h, RDW24h red cell distribution width at 24 h, U univariate analysis, WBC white blood cells
  2. a Only presented significant comorbidities in univariate analysis; Comorbidities evaluated: Neurological, cardiovascular, respiratory and gastrointestinal conditions, malignancy and immunosuppression